NEW HAVEN, Conn., Oct. 11 /PRNewswire/ -- RHEI Pharmaceuticals, Inc., a venture backed company focused on introducing approved and late clinical-stage proprietary drugs from the US into China, announced today that Timothy M. Kish has joined the company as President and CFO.
Mr. Kish has more than 20 years of senior management experience in building successful businesses in the life science industry. From 1986 to 2000, he was at Biogen, Inc (now Biogen IDEC) as it grew from a research organization to nearly one billion dollars of revenues, most recently as Vice President and Chief Financial Officer. From 2000 to 2005, he was Vice President and CFO of Illumina, Inc, a leading provider of instrumentation and consumables to the genetic analysis and personalized medicine markets. In both cases, he played a key role in the major strategic and operational activities of those companies, was instrumental in raising hundred’s of millions of dollars in financing and was responsible for all financial activities as well as several other functions. During the last year, he was President of TMK Advisors, an investor in and consultant to the life science industry.
“We are very pleased to bring someone with Tim’s experience into RHEI,” said Dr. Sylvia (Xin) He, RHEI’s founder and Chief Executive Officer. “Tim’s solid expertise in finance and multinational operations completes a critical component for RHEI. Our in-licensing efforts are accelerating. The addition of Tim to our team will help us rapidly achieve our vision of making RHEI the number one independent player in the Chinese proprietary pharmaceutical market.”
“Tim brings a significant background in growing life science companies to RHEI that will prove invaluable in our efforts to make RHEI Pharmaceuticals into a leading Chinese pharmaceutical company,” said RHEI Chairman and co- founder, Harry H. Penner, Jr. “Tim will be a great complement to the strong team already in place.”
“RHEI represents a remarkable opportunity,” stated Mr. Kish. “The company has an outstanding network of individuals in China that provide a significant competitive edge in the drug development and approval process, an operational base that includes a Chinese GMP manufacturing facility and over 100 sales people, and two in-licensed products as well as a number of other approved or late-stage product candidates currently under negotiation. I look forward to working with Harry, Sylvia and the board to help build RHEI into a large and successful, multi-national pharmaceutical company.”
About RHEI Pharmaceuticals
RHEI Pharmaceuticals is a venture backed specialty pharmaceutical company with operations in the U.S. and in China that acquires, licenses, develops and commercializes in China proprietary drug therapies based upon the unmet needs of the emerging China pharmaceuticals market. RHEI leverages its proprietary and extensive network of experienced clinical development and regulatory professionals in China to expedite approvals for pharmaceuticals new to the China market. RHEI’s growing sales and marketing capabilities then provide broad patient access in China to these new and critically necessary therapeutics. RHEI specializes in hospital-based proprietary products with a therapeutic focus on urgent unmet needs in the areas of cancer, cardiovascular disease, neurology, anti-infectives, and other life threatening conditions.
Source: RHEI Pharmaceuticals, Inc.
